Focusing the mechanism of action to dissect the different treatments of respiratory allergy

References

• Asher MI, Montefort S, Bjorksten B, et al. ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368(9537):733-43
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
   PubMed Web of Science ®Google Scholar
• Braman SS. The global burden of asthma. Chest 2006;130(1 Suppl):4S-12S
   PubMed Web of Science ®Google Scholar
• Blaiss MS. Allergic rhinitis: direct and indirect costs. Allergy Asthma Proc 2010;31(5):375-80
   PubMed Web of Science ®Google Scholar
• Schwindt CD, Settipane R. Allergic rhinitis (AR) is now estimated to affect some 1.4 billion people globally and continues to be on the rise. Editorial. Am J Rhinol Allergy 2012;26:Suppl 1
   PubMedGoogle Scholar
• GINA. Global strategy for asthma management and prevention. Global Initiative for asthma 2014. Available from: www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf [Last accessed 06 February 2015]
   Google Scholar
• Moreira A, Bonini M, Pawankar R, et al. A World Allergy Organization international survey on physical activity as a treatment option for asthma and allergies. World Allergy Organ J 2014;7(1):34
   Google Scholar
• O’Meara TJ, Sercombe JK, Morgan G, et al. The reduction of rhinitis symptoms by nasal filters during natural exposure to ragweed and grass pollen. Allergy 2005;60(4):529-32
   PubMed Web of Science ®Google Scholar
• Sheikh A, Hurwitz B, Nurmatov U, et al. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev 2010(7):CD001563
   Google Scholar
• Grootendorst DC, Dahlen SE, Van Den Bos JW, et al. Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids. Clin Exp Allergy 2001;31(3):400-8
   PubMed Web of Science ®Google Scholar
• Bousquet J, Van Cauwenberge P, Khaltaev N; ARIA Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl):S147-334
   PubMed Web of Science ®Google Scholar
• Church DS, Church MK. Pharmacology of antihistamines. WAO J 2011;4(3 Suppl):22-7
   Google Scholar
• Simons FE. Advances in H1-antihistamines. N Engl J Med 2004;351(21):2203-17
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011;128(6):1139-50
   PubMed Web of Science ®Google Scholar
• Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122(Suppl 2):S1-84
   Google Scholar
• Vasiadi M, Kalogeromitros D, Kempuraj D, et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. Int Arch Allergy Immunol 2010;151(1):38-45
   PubMed Web of Science ®Google Scholar
• Stuebner P, Horak F, Zieglmayer R, et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol 2006;96(1):37-44
   PubMed Web of Science ®Google Scholar
• Davila I, Sastre J, Mullol J, et al. Effect of bilastine on nasal obstruction. J Investig Allergol Clin Immunol 2011;21(Suppl 3):2-8
   PubMed Web of Science ®Google Scholar
• Ridolo E, Montagni M, Bonzano L, et al. Bilastine: new insight into antihistamine treatment. Clin Mol Allergy 2015;13:1
   PubMedGoogle Scholar
• Ridolo E, Montagni M, Melli V, et al. Pharmacotherapy of allergic rhinitis: current options and future perspectives. Expert Opin Pharmacother 2014;15(1):73-83
   PubMed Web of Science ®Google Scholar
• Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008;63(10):1292-300
   PubMed Web of Science ®Google Scholar
• Wolthers OD. Relevance of pharmacokinetics and bioavailability of intranasal corticosteroids in allergic rhinitis. Recent Pat Inflamm Allergy Drug Discov 2010;4(2):118-23
   PubMedGoogle Scholar
• Blaiss MS. Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc 2007;28(2):145-52
   PubMed Web of Science ®Google Scholar
• Penagos M, Compalati E, Tarantini F, et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy 2008;63(10):1280-91
   PubMed Web of Science ®Google Scholar
• Chopra D, Bhandari B, Wardhan N. Ciclesonide – a novel corticosteroid for the management of asthma. Curr Clin Pharmacol 2012;7(2):73-7
   PubMedGoogle Scholar
• Neffen H, Wingertzahn MA. Ciclesonide, a hypotonic intranasal corticosteroid. Allergy Asthma Proc 2010;31(4):354
   Web of Science ®Google Scholar
• Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis. Allergy 2013;68(5):569-79
   PubMed Web of Science ®Google Scholar
• Meltzer EO, LaForce C, Ratner P, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc 2012;33(4):324-32
   PubMed Web of Science ®Google Scholar
• Bernstein JA. MP29-02: a breakthrough for the treatment of allergic rhinitis. Expert Opin Pharmacother 2013;14(1):2101-13
   PubMedGoogle Scholar
• Derendorf H, Meltzer EO, Hermann R, Canonica GW. Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. Drugs Today (Barc) 2014;50(1):15-31
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. A placebo-controlled study of the nasal decongestant effect of Phenylepherine and Pseudoephedrine in the Vienna challenge chamber. Ann Allergy Asthma Immunmol 2009;102(2):116-20
   PubMed Web of Science ®Google Scholar
• Wellington K, Jarvis B. Cetirizine/pseudoephedrine. Drugs 2001;61(15):2231-40
   PubMedGoogle Scholar
• Varghese M, Glaum MC, Lockey RF. Drug-induced rhinitis. Clin Exp Allergy 2010;40(3):381-4
   PubMed Web of Science ®Google Scholar
• Kremer B, Tündermann A, Goldschmidt O. Onset of action, effectiveness and tolerance of levocabastine and nedocromil in topical therapy pf seasonal allergic rhinoconjunctivitis. The Deutsche Rhinitis-Studiengruppe. Arzneimittelforschung 1998;48(9):924-30
   PubMed Web of Science ®Google Scholar
• van der Wouden JC, Uijen JH, Bernsen RM, et al. Inhaled sodium chromoglycate for asthma in children. Cochrane Database Syst Rev 2008(4):CD00217
   Google Scholar
• Sridar AV, McKean M. Nedocromil sodium for chronic asthma in children. Cochrane Database Syst Rev 2006(3):CD004108
   Google Scholar
• Tamm M, Richards DH, Beghè B, Fabbri L. Inhaled corticosteroids and long-acting beta2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med 2012;106(Suppl 1):9-19
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am 2005;25(3):451-68
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock IM, Ito K. Hystone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Resp J 2005;25(3):552-63
   PubMed Web of Science ®Google Scholar
• Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir Med 2006;100(8):1297-306
   PubMed Web of Science ®Google Scholar
• Hallstrand TS, Henderson WRJr. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 2010;10(1):60-6
   PubMed Web of Science ®Google Scholar
• Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012;5:CD002314
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Fitzharris P, Cromwell O, et al. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB4 in allergic rhinitis. Allergy 1985;40(1):1-6
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extension. Pediatr Pulmonol 2009;44(6):568-79
   PubMed Web of Science ®Google Scholar
• Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007;67(6):887-901
   PubMed Web of Science ®Google Scholar
• Hay J, Jhaveri M, Targilala M, Kaliner M. Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. Allergy Asthma Proc 2009;30(6):634-42
   PubMed Web of Science ®Google Scholar
• Soler X, Ramsdell J. Anticholinergic/antimuscarinic drugs in asthma. Curr Allergy Asthma Rep 2014;14:484-8
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2014;15(7):961-77
   PubMed Web of Science ®Google Scholar
• Guyer AC, Long AA. Long-acting anticholinergics in the treatment of asthma. Curr Opin Allergy Clin Immunol 2013;13(4):392-8
   PubMed Web of Science ®Google Scholar
• Milgrom H, Biondi R, Georgitis JW, et al. Comparison of ipratropium bromide 0.03% with beclomethasone dipropionate in the treatment of perennial rhinitis in children. Ann Allergy Asthma Immunol 1999;83(2):105-11
   PubMed Web of Science ®Google Scholar
• Hanania NA, Dickey BF, Bond RA. Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med 2010;16(1):1-5
   PubMed Web of Science ®Google Scholar
• Walters EH, Gibson PG, Lasserson TJ, et al. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007;24(1):CD00138
   Google Scholar
• Hizawa N. Pharmacogenetics of β2agonists. Allergol Int 2011;60(3):239-46
   PubMedGoogle Scholar
• McKeage K. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs 2013;73(11):1197-212
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Mauro M, Russello M, et al. Omalizumab, and anti-immunoglobulin E antibody: state of the art. Drug Des Devel Ther 2014;8:197-207
   PubMed Web of Science ®Google Scholar
• Casale TB, Condemi J, LaForce C, et al. Omalizumab Seasonal Allergic Rhinitis Trail Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001;286(23):2956-67
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti- IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91(2):160-7
   PubMed Web of Science ®Google Scholar
• Tsabouri S, Tseretopoulou X, Priftis K, et al. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract 2014;2(3):332-40
   PubMed Web of Science ®Google Scholar
• Canonica GW, Passalacqua G. Disease-modifying effect and economic evaluation of sublingual immunotherapy. J Allergy Clin Immunol 2011;127(1):44-5
   PubMed Web of Science ®Google Scholar
• Viswanathan RK, Busse WW. Allergen immunotherapy in allergic respiratory diseases: from mechanisms of action to meta-analyses. Chest 2012;141(5):1303-14
   PubMed Web of Science ®Google Scholar
• Compalati E, Penagos M, Tarantini F, et al. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol 2009;102(1):22-8
   PubMed Web of Science ®Google Scholar
• Frati F, Dell’Albani I, Incorvaia C. Long-term efficacy of allergen immunotherapy: what do we expect? Immunotherapy 2013;5(2):131-3
   PubMed Web of Science ®Google Scholar
• Jacobsen L, Niggemann B, Dreborg S, et al. The PAT investigator group. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62(8):943-8
   PubMed Web of Science ®Google Scholar
• Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO Position Paper. J Allergy Clin Immunol 1998;102(4):558-62
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bousquet J, Casale T. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009;64(Suppl 91):1-59
   PubMed Web of Science ®Google Scholar
• Dretzke J, Meadows A, Novielli N, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 2013;131(5):1361-6
   PubMed Web of Science ®Google Scholar
• Amin H, Liss G, Bernstein D. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006;117(1):169-75
   PubMed Web of Science ®Google Scholar
• Schiappoli M, Ridolo E, Senna G, et al. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clin Exp Allergy 2009;39(10):1569-74
   PubMed Web of Science ®Google Scholar
• Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117(1):134-40
   PubMed Web of Science ®Google Scholar
• Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109(2):274-80
   PubMed Web of Science ®Google Scholar
• Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009;39(2):271-9
   PubMed Web of Science ®Google Scholar
• Gidaro GB, Marcucci F, Sensi L, et al. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005;35(5):565-71
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Guerra L, Compalati E, et al. The safety of allergen specific sublingual immunotherapy. Curr Drug Saf 2007;2(2):117-23
   PubMedGoogle Scholar
• Tahamiler R, Saritzali G, Canakcioglu S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope 2007;117(6):965-9
   PubMed Web of Science ®Google Scholar
• Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010;126(5):969-75
   PubMed Web of Science ®Google Scholar
• Manzotti G, Pappacoda A, Dimatteo M, et al. Ultra short pre-seasonal subcutaneous and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient’s preference in real life. Eur Ann Allergy Clin Immunol 2013;45(4):138-44
   PubMedGoogle Scholar
• Okano M. Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis. Clin Exp Immunol 2009;158(2):164-73
   PubMed Web of Science ®Google Scholar
• Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy 2011;66(6):725-32
   PubMed Web of Science ®Google Scholar
• Jay DC, Nadeau KC. Immune mechanisms of sublingual immunotherapy. Curr Allergy Asthma Rep 2014;14(11):473
   PubMed Web of Science ®Google Scholar
• Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006;354(19):1985-97
   PubMed Web of Science ®Google Scholar
• Passalacqua G. Specific immunotherapy in asthma: a comprehensive review. J Asthma 2014;51(1):29-33
   PubMed Web of Science ®Google Scholar
• Devillier P, Dreyfus JF, Demoly P, et al. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med 2014;12-71
   PubMedGoogle Scholar
• Olin JT, Wechsler ME. Asthma: pathogenesis and novel drugs for treatment. BMJ 2014;349:g5517
   PubMed Web of Science ®Google Scholar
• Aryan Z, Holgate ST, Radzioch D, et al. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol 2014;164(1):46-63
   PubMed Web of Science ®Google Scholar
• Pajno GB, Nadeau KC, Passalacqua G, et al. The evolution of allergen and non-specific immunotherapy: past achievements, current application and future outlook. Expert Rev Clin Immunol 2015;11(1):141-54
   PubMed Web of Science ®Google Scholar